These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 30666432)
1. The incidence and risk factors of hepatic veno-occlusive disease after hematopoietic stem cell transplantation in Taiwan. Lee CC; Chang HH; Lu MY; Yang YL; Chou SW; Lin DT; Jou ST; Yao M; Li CC; Yeh SP; Chen MH; Gau JP; Li SS; Wang PN; Liu YC; Wang TF; Tan TD; Lee MY; Yu MS; Wang CC; Lin SC; Chen YC; Su YC; Su KY; Lin KH Ann Hematol; 2019 Mar; 98(3):745-752. PubMed ID: 30666432 [TBL] [Abstract][Full Text] [Related]
2. Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children: a retrospective study of the Italian Hematology-Oncology Association-Hematopoietic Stem Cell Transplantation Group. Faraci M; Bertaina A; Luksch R; Calore E; Lanino E; Saglio F; Prete A; Menconi M; De Simone G; Tintori V; Cesaro S; Santarone S; Orofino MG; Locatelli F; Zecca M Biol Blood Marrow Transplant; 2019 Feb; 25(2):313-320. PubMed ID: 30266674 [TBL] [Abstract][Full Text] [Related]
5. Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children. Song JS; Seo JJ; Moon HN; Ghim T; Im HJ J Korean Med Sci; 2006 Oct; 21(5):897-903. PubMed ID: 17043426 [TBL] [Abstract][Full Text] [Related]
6. Busulfan clearance does not predict the development of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation. Salman B; Al-Khabori M; Al-Huneini M; Al-Rawas A; Dennison D; Al-Za'abi M Int J Hematol; 2020 Aug; 112(2):210-216. PubMed ID: 32468179 [TBL] [Abstract][Full Text] [Related]
7. Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years. Kalayoglu-Besisik S; Yenerel MN; Caliskan Y; Ozturk S; Besisik F; Sargin D Transplant Proc; 2005 Jun; 37(5):2285-9. PubMed ID: 15964400 [TBL] [Abstract][Full Text] [Related]
8. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Cesaro S; Pillon M; Talenti E; Toffolutti T; Calore E; Tridello G; Strugo L; Destro R; Gazzola MV; Varotto S; Errigo G; Carli M; Zanesco L; Messina C Haematologica; 2005 Oct; 90(10):1396-404. PubMed ID: 16219577 [TBL] [Abstract][Full Text] [Related]
9. Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment. Dalle JH; Giralt SA Biol Blood Marrow Transplant; 2016 Mar; 22(3):400-9. PubMed ID: 26431626 [TBL] [Abstract][Full Text] [Related]
10. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Shore T; Iacobelli M; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ; Biol Blood Marrow Transplant; 2017 Jun; 23(6):997-1004. PubMed ID: 28285079 [TBL] [Abstract][Full Text] [Related]
11. Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: A Study on Behalf of the Spanish Hematopoietic Stem Cell Transplantation and Cellular Therapy Group (GETH). Gómez-Centurión I; Gallardo Morillo AI; Pérez Martínez A; Cabrero Calvo M; Chinea A; González L; Pedraza A; Jiménez Lorenzo MJ; Robles MC; Bailén R; Cascón MJP; Cabero A; Piñana Sánchez JL; Luna A; Perera Alvarez M; Rovira M; Torrent Catarineu A; Sánchez-Pina J; Kwon M Transplant Cell Ther; 2024 Sep; 30(9):914.e1-914.e8. PubMed ID: 38851323 [TBL] [Abstract][Full Text] [Related]
12. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection. Moscardó F; Sanz GF; de La Rubia J; Jiménez C; Saavedra S; Regadera A; Andreu R; García I; Plumé G; Martínez J; Martín G; Jarque I; Sanz MA Bone Marrow Transplant; 2001 May; 27(9):983-8. PubMed ID: 11436110 [TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Defibrotide in the Prophylaxis of Veno-Occlusive Disease after Pediatric Allogeneic Stem Cell Transplantation. Pichler H; Horner K; Engstler G; Poetschger U; Glogova E; Karlhuber S; Martin M; Eibler W; Witt V; Holter W; Matthes-Martin S Biol Blood Marrow Transplant; 2017 Jul; 23(7):1128-1133. PubMed ID: 28359910 [TBL] [Abstract][Full Text] [Related]
14. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Carreras E; Díaz-Beyá M; Rosiñol L; Martínez C; Fernández-Avilés F; Rovira M Biol Blood Marrow Transplant; 2011 Nov; 17(11):1713-20. PubMed ID: 21708110 [TBL] [Abstract][Full Text] [Related]
15. Association of IL-1β -511 polymorphism with severe veno-occlusive disease in pediatric-matched allogeneic hematopoietic stem cell transplantation. Elbahlawan L; McArthur J; Quasney MW; Pei D; Srivastava K; Dahmer MK; Barfield R J Pediatr Hematol Oncol; 2012 Apr; 34(3):175-9. PubMed ID: 22395218 [TBL] [Abstract][Full Text] [Related]
16. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Carreras E; Bertz H; Arcese W; Vernant JP; Tomás JF; Hagglund H; Bandini G; Esperou H; Russell J; de la Rubia J; Di Girolamo G; Demuynck H; Hartmann O; Clausen J; Ruutu T; Leblond V; Iriondo A; Bosi A; Ben-Bassat I; Koza V; Gratwohl A; Apperley JF Blood; 1998 Nov; 92(10):3599-604. PubMed ID: 9808553 [TBL] [Abstract][Full Text] [Related]
17. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Lee JL; Gooley T; Bensinger W; Schiffman K; McDonald GB Biol Blood Marrow Transplant; 1999; 5(5):306-15. PubMed ID: 10534061 [TBL] [Abstract][Full Text] [Related]
18. Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Lee SH; Yoo KH; Sung KW; Koo HH; Kwon YJ; Kwon MM; Park HJ; Park BK; Kim YY; Park JA; Im HJ; Seo JJ; Kang HJ; Shin HY; Ahn HS Bone Marrow Transplant; 2010 Aug; 45(8):1287-93. PubMed ID: 20010866 [TBL] [Abstract][Full Text] [Related]
19. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study. Tanikawa S; Mori S; Ohhashi K; Akiyama H; Sasaki T; Kaku H; Hiruma K; Matsunaga T; Morita T; Sakamaki H Bone Marrow Transplant; 2000 Oct; 26(8):881-6. PubMed ID: 11081389 [TBL] [Abstract][Full Text] [Related]
20. Veno-occlusive disease in children and adolescents after hematopoietic stem cell transplantation: Did the Modified Seattle Criteria fit the characteristics of pediatric population? Szmit Z; Gorczyńska E; Mielcarek-Siedziuk M; Ussowicz M; Owoc-Lempach J; Kałwak K Adv Clin Exp Med; 2020 Mar; 29(3):339-344. PubMed ID: 32207590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]